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MitochondriaMethotrexate has been in use as an anti-cancer agent for over 60 years. Though inhibition of dihydrofolate reduc-
tase is its best known mechanisms of action, its non-dihydrofolate reductase dependent mechanisms disrupt
metabolic pathways resulting in a depletion of NAD(P)H and increasing oxidative stress. These mechanisms
highlight a novel dependence of cancer cells on their metabolic abnormalities to buffer oxidative stress and che-
motherapeutic agents interfere with these cellular abilities. Mitochondria appear to play a signiﬁcant role in
maintaining cancer cell viability and alterations inmetabolism seen in cancer cells aid this mitochondrial ability.
Further research is needed to understand the effects of other chemotherapeutic agents on these pathways.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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The origins of modern day chemotherapy can be traced back to the
early days of World War II. On December 2, 1943, the port of Bari,
Italy was the target of a German air raid on Allied forces [1–3]. The casu-
alties of this air raid far outnumbered those expected for the size of the
attack. Though banned by the Geneva Protocol of 1925, Allied forces
were concernedwith the possibility that theGerman armywould resort. This is an open access article underto the use of chemical weapons. In August of 1943, President Roosevelt
approved the shipment of a secret cargo of mustard gas via SS Harvey.
The explosion of the ship during this raid released its contents onto
the city inﬂicting an untold number of civilian casualties. With some
variation in details depending on the source, investigations by Dr.
Stewart Francis Alexander, a Lieutenant Colonel and expert in chemical
warfare noted signiﬁcant suppression of both lymphoid and myeloid
tissues in those exposed to the chemical agent [1]. Later research with
a related compound, mustine, led to successful reduction of tumor
mass in a patient with non-Hodgkin's lymphoma and to a realization
that pharmacotherapy of cancers was feasible.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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made by a pathologist at Harvard Medical School. Sidney Farber had
studied the stimulating effect of folic acid on the proliferation of acute
lymphoblastic leukemia cells when given to children with this cancer
[4]. At that time, knowledge of the role of folic acid was limited to its
effect as a cofactor in the synthesis of purines. This observation led to
one of the ﬁrst attempts at rational drug design. In collaboration with
the ﬁrst chemists to successfully synthesize folic acid at Lederle Labora-
tories, Farber helped design the folate analog aminopterin [4,3]. Later,
this collaboration led to the synthesis of the antibiotic trimethoprim
and the chemotherapeutic agent amethopterin, more famously known
as methotrexate [4]. Since that time, the intracellular biochemistries of
both folic acid and methotrexate have been further explored and
detailed.
The classically taught mechanism of action for methotrexate is inhi-
bition of dihydrofolate reductase (DHFR) to deplete cellular pools of
tetrahydrofolate and stop the production of thymidylate. Cells lacking
adequate thymidine are unable to synthesize DNA, which results in
the arrest of cellular proliferation. The combined effect is thought to
lead to the demise of rapidly dividing cell populations either through
apoptosis or autophagy. In cancer therapy, sustained maximal DHFR
inhibition is targeted and important for several reasons. First, it provides
steady inhibition of DNA synthesis, and, second, it minimizes the risk of
developing resistance to MTX [5]. With only 1% of the average cellular
DHFR concentration required tomaintain a sufﬁcient reserve of reduced
folate coenzymes, high doses of MTX are required to achieve this effect
and are frequently limited by toxicities [6].Major adverse effects ofMTX
therapy include dermatitis, elevated transaminases, mucositis, and
myelosuppression. Leucovorin, a folate derivative that bypasses theFig. 1. Effects of methotrexate on folate metabolism in relation to nucleotidemetabolism. Via it
rahydrofolate and subsequently, DNA synthesis. Tetrahydrofolate ismetabolized further for use
frommethotrexate and restore cellular stores of tetrahydrofolate. In addition to interference w
the metabolism of purines. Legend: ADP, adenosine diphosphate; AMP, adenosine monophosp
phate;DHFR, dihydrofolate reductase; dTMP, deoxythimidinemonophosphate; dUDP, deoxyuri
guaninemonophosphate;HGPRT, hypoxanthine-guaninephosphoribosyltransferase; IMP, inosi
nucleotide phosphorylase; PRPP, phosphoribosyl pyrophosphate; UDP, uracil diphosphate; UMDHFR reaction, is used as a rescue agent to curb the incidence and
severity of these effects and often found in high dose MTX protocols
(see Fig. 1).
The in vitro mechanics of the anti-folate MTX on DHFR are well
known. Newer studies reveal in vivo biochemical interactions of MTX
with multiple enzymes. They describe interactions of MTX with multi-
ple metabolic pathways ranging from cellular energy production, anti-
oxidant regeneration, nucleotide synthesis and buffering of oxidative
stress [7,8,6]. This review will describe the peculiarities of cancer
metabolism and the non-DHFRmechanisms of MTX. These interactions
support the hypothesis that mitochondria and this organelle's function
in buffering of oxidative stress. In addition to dysfunctional glycolysis,
this mitochondrial function appears to have a signiﬁcant inﬂuence on
the cancer cell's metabolism and themechanisms of other chemothera-
peutic agents.2. Methods
Online literature searches of PubMed and Google Scholar were per-
formed using the following terms and related biochemical pathways:
autophagy, aerobic glycolysis, cancer metabolism, hydrogenosomes,
glutamine metabolism, methotrexate, mitophagy, oxidative stress and
cellular redox balance. No limitations were placed on the date of publi-
cation. Though the number of search results was not recorded, approx-
imately 1800 publications were reviewed. The types of manuscripts
included reviews, original research and letters to editor with both clin-
ical and pre-clinical data. Historical texts and materials were reviewed
in order to provide insight into the origins of chemotherapeutic agents.s inhibition of dihydrofolate reductase, methotrexate interferes with the generation of tet-
as a cofactor in the synthesis of dTMP. Folinic acid, leucovorin, is often used to rescue cells
ith DNA synthesis, this diagram superﬁcially shows the involvement of tetrahydrofolate in
hate; CDP, cytidine diphosphate; CTP, cytidine triphosphate; dCDP, deoxycytidine diphos-
dinediphosphate; dUMP, deoxyuridinemonophosphate; GDP, guanine diphosphate; GMP,
nemonophosphate;Methyl THF,methyltetrahydrofolate;MTX,methotrexate; PNP, purine
P, uracil monophosphate; UTP, uracil triphosphate; XMP, xanthine monophosphate.
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search for human trials of similar therapeutic scenarios.
3. Metabolic dysfunction of the cancer cell and the Warburg effect
Otto Warburg was awarded the 1931 Nobel Prize for Physiology or
Medicine as a result of his research on cellular respiration. He hypothe-
sized that cancerous transformation of tissue was a result of an injured
respiration, ormetabolism. This hypothesis, referred to as “TheWarburg
Effect”, describes a dysfunctional metabolic state dominated by glycoly-
sis ending in lactate production and present in a variety of cancers [9,
10]. Warburg postulated that this dysfunctional metabolism was the
primary cause of cancer. Cancer cell research has since characterized a
complex state of metabolic disarray involving glycolysis, the pentose
phosphate pathway, the tricarboxylic acid (TCA) cycle, the electron
transport chain and amino acid metabolism [11,6,12–14]. The derange-
ments seen in cancer cells result from a combination of factors including
hypoxia, poor total body and cellular antioxidant reserve,mitochondrial
dysfunction and free radical production.
The elementary differences between normal and tumor cell metab-
olism are characterized by increased glycolytic ﬂux even in the presence
of adequate oxygen [14]. This change in cellular metabolism is oft
considered a result, not an instigator, of cancerous transformation.
However, the idea of metabolic disarray as an initiator of cancer has
gained additional support in recent years [14]. The metabolic ratios of
glycolysis and mitochondrial oxidative respiration in transformed cells
show similarities to proliferating non-transformed cells but the ability
of transformed cells to return to non-Warburg, or non-stressed, meta-
bolic proﬁle is hindered. Somemay argue against this theory as oxygen
consumption in these transformed cells continues despite the produc-
tion of ATP via aerobic glycolysis [15]. The perturbed metabolism of
transformed cells does not fully exclude oxidative phosphorylation as
a source of ATP production but cellular oxygen tension, or lack thereof,
does inﬂuence these cellular processes.
Under normal oxygen tension, hypoxia-inducible factor alpha (HIF-
1α) is produced and degraded at an equal rate. The Von Hippel–Lindau
tumor suppressor gene product, pVHL, has multiple functions, one of
which is a recognition subunit of an E3 ubiquitin ligase complex. Prolyl
hydroxylases (PHD) catalyze the hydroxylation of proline residues on
the oxygen-dependent degradation site of HIF-1α creating a docking
site for pVHL directed degradation [16]. Degradation of HIF-1α via
pVHL is an oxygen-dependent process, converting oxygen and α-
ketoglutarate to carbon dioxide, and is a rate-limiting reaction
dependent on the functional capacity of pVHL [17]. In the absence of
sufﬁcient reactants the HIF-1α protein stabilizes, binds HIF-b and is
transported to the nucleus where it stimulates the transcription
of genes containing the hypoxia response element. Stabilization of
HIF-1α outside of a true hypoxic environment is referred to as
pseudohypoxia. The pseudohypoxic phenotype has been seen in associ-
ation with alterations in TCA associated enzymes and may lead to
changes in epigenetic homeostasis with tumor promoting effects [14].
Both succinate dehydrogenase and fumarate dehydrogenase possess
tumor suppressing functions and loss of these functions has been
observed in many VHL-associated renal tumors [16]. The defects of
these mitochondrial enzymes may be from inhibition exogenous to
the enzyme, such as inactivation through reaction with free radicals,
or a functional defect secondary to genetic mutation.
The HIF transcription cascade results in increased synthesis of
glucose transporters GLUT1 and GLUT3, 6-phosphofructo-2-kinase,
phosphoglycerate kinase 1, pyruvate kinase M2, monocarboxylate
transporter MCT4 (a lactate efﬂux pump), and pyruvate dehydrogenase
kinase (PDK1). When phosphorylated by PDK1, the pyruvate dehydro-
genase enzyme is inactivated and this inhibits the conversion of pyru-
vate into acetyl-CoA for the TCA cycle [18]. Despite a lack of glycolysis
derived acetyl-CoA, TCA cycle activity continues. In oxygen concentra-
tions as low as 1%, NADH production maintains a normal rate withmitochondrial ATP production signiﬁcantly reduced [19]. As GLUT1
and GLUT3 maintain an insulin-independent inﬂux of glucose, activa-
tion of insulin receptorswould be associatedwith amuch larger volume
of raw materials for its metabolic processes. If the cell remains
normoxic, aberrantly expressed PDK1 blocks delivery of glycolysis
derived substrate to the TCA cycle. Mitochondria in the pseudohypoxic
cell become starved for materials begin catabolizing amino acids, such
as glutamine and asparagine, to supply the TCA cycle with intermedi-
ates, a-ketoglutarate and oxaloacetate respectively [20,21,13].
The change in fuel source and pathwaymay offer an explanation for
the inverse relationship between the aggressiveness in tumor growth
and proliferation and the drop in serum glutamine concentrations
[22]. The conversion of amino acids to TCA intermediates has been
seen as glutamine derived carbon exiting the TCA cycle as malic acid
and being catalyzed by malic enzymes to produce NADPH; a reactant
in the regeneration of free radical scavengers like glutathione [23]. The
catabolism of glutamine and asparagine seen in highlymetabolically ac-
tive cancers is likely due to the ease with which they are transaminated
to supply TCA intermediates. Additionally, high concentrations of pyru-
vate serve as a sink for nitrogen freed from amino acid transaminations
[24].4. Methotrexate
MTX is an inhibitor of dihydrofolate reductase and, more generally
speaking, many NAD(P)H-dependent oxidoreductases. Unfortunately,
its clinical use is associated with various toxicities. High doses of MTX
are required to induce inhibition of the entire cellular pool of DHFR
and are often associatedwith increased frequency and severity of its ad-
verse effects [6]. Folinic acid, or leucovorin, has long been used to rescue
cells from MTX toxicity and sidesteps the DHFR blockade in the cell.
Beyond very high dose leucovorin rescues, few reports can be found of
markedly reducedMTX efﬁcacywith low dose leucovorin or concurrent
folate supplementation. This suggests methotrexate toxicity and
pharmacokinetics in chemotherapy may be secondary to its effects on
cellular abilities to buffer oxidative ﬂux via non-DHFR mechanisms.
Multiple studies report various “antioxidant” therapies using quercetin,
L-carnitine, lipoic acid, melatonin, and curcumin are effective in reduc-
ing MTX toxicity [25,11,26–28].
Dihydrofolate reductase is an NADPH-dependent oxidoreductase
that oxidizes NADPH to NADP+ while reducing dihydrofolic acid to
tetrahydrofolic acid. Reversing the reaction, this same enzyme can
be referred to as tetrahydrofolate dehydrogenase, anNADP+-dependent
enzyme. In addition to DHFR, MTX inhibits many NAD(P)-dehydro-
genase enzymes; glucose-6-phosphate dehydrogenase (G6PD), 6-
phosphogluconate dehydrogenase (6PGD), pyruvate dehydrogenase,
isocitrate dehydrogenase, alpha-ketoglutarate dehydrogenase, andma-
late dehydrogenase [11,29,7,8,6,28] (see Fig. 2). There is a synergistic
inhibitory effect on several enzymes more directly involved withmain-
tenance of the cellular redox state via the regeneration of glutathione.
Glutathione reductase, gamma-glutamylcysteine synthetase, glutathi-
one peroxidase and lactate dehydrogenase are also inhibited on a
concentration dependent manner by MTX with no effect from co-
administered leucovorin [6] (see Table 1).
These NAD-dependent dehydrogenase enzymes have conserved
super-secondary structures with varying subunits [30]. While all are re-
lated in regard to this structure, differences lie in individual enzyme
subunits. These subunits may be responsible for the variable responses
to methotrexate and its polyglutamates. The function of the enzymes in
this studywasmeasured by the rate of NAD(P)H oxidation at increasing
MTX concentrations. Direct comparison of MTX's inhibitory effects on
the activity of DHFR is difﬁcult as studies using the same result measure
could not be found. The serum concentrations of methotrexate seen in
the table, however, are frequently reached in high dose methotrexate
administrations.
Fig. 2. An overview of carbon metabolism with enzymes affected by methotrexate. MTX can be seen inhibiting many enzymes involved in glucose metabolism. The enzymes inhibited in
this ﬁgure are all dehydrogenase enzymes and involved in reduction of NAD+/NADP+ to NADH/NADPH. These reduced compounds are involved in multiple cellular reactions, the
regeneration of reduced glutathione being one of them. Also seen in this ﬁgure is the incorporation of asparagine and glutamine as carbon sources for the production of TCA cycle
intermediates. Legend: NAD+, nicotinamide adenine dinucleotide; NADP+, nicotinamide adenine dinucleotide phosphate; NADH, reduced nicotinamide adenine dinucleotide;
NADPH, reduced nicotinamide adenine dinucleotide phosphate; star-shape indicates reaction of multiple reactants and products with various intermediates. Dashed lines indicate a
metabolite is present in two locations along the metabolic pathway. Bold lines indicate an irreversible reaction.
Table 1
Inhibitory effect of methotrexate on NADPH-dependent oxidoreductases [6].
Enzyme [MTX] μM Activity
2-Oxaloglutarate dehydrogenase 15 50%
100 0%
Isocitrate dehydrogenase 100 50%
500 0%
Malate dehydrogenase 150 50%
400 0%
Succinate dehydrogenase 500 80%
Glutathione reductase
CFE-HeLa cell enzyme 80 50%
250 10%
Puriﬁed enzyme 110 50%
200 20%
6-Phosphogluconate dehydrogenase
CFE-Hela cell enzyme 50 50%
200 10%
Puriﬁed enzyme 100 50%
Glucose-6-phosphate dehydrogenase
CFE-Hela cell enzyme 100 50%
250 10%
Puriﬁed enzyme 100 50%
250 10%
Gamma-glutamylcysteine synthetase 100 46%
Glutathione peroxidase 100 50%
Values in this table were obtained directly from the text or via interpretation of ﬁgures in
the reference.
155J.A. Hess, M.K. Khasawneh / BBA Clinical 3 (2015) 152–161Both G6PD and 6PGD enzymes catalyze the reduction of NAD(P)+
to NAD(P)H in the pentose phosphate pathway for eventual use in
either the reduction of oxidized glutathione, the production of a free
radicals via NADPH oxidase, cholesterol production, steroidogenesis,
etc. The remaining enzymes are largely involved in TCA cycle reactions
resulting in the reduction of NAD+ to NADH within the mitochondria.
In proliferating cells, the pentose phosphate pathway and actions of
malic enzyme are currently considered the most signiﬁcant source of
cellular NAD(P)+ regeneration [6]. With the blockage of these
enzymes, the cellular ability to regenerate glutathione, and deal with
oxidative stress, is inhibited. Highlighting the dependence of cells on
glutamine in dealing with oxidative stress, the loss of glutaminase-2
production leads to decreasedNAD(P)Hproduction, decreased glutathi-
one production and sensitizes cancer cells to oxidative stresses like
those induced by ionizing radiation [31]. As MTX doses increase, they
impose a greater oxidant buffering handicap, proving fatal for both nor-
mal and abnormal cells. Cellular depletion of NAD(P)H leading to cell
death is also seen in the treatment of infectious diseases. Antimicrobial
therapy of both Gram negative and Gram positive organisms with bac-
tericidal, but not bacteriostatic, antibiotics leads to a transient depletion
of NADH, increased oxidative stress and ultimately cell death [32].
In vivoMTXmetabolism follows a similar pathway to natural folates
with polyglutamation via the enzyme folylpolyglutamyl synthetase [33,
34]. MTX polyglutamates, especially with three or more glutamate
residues, are retained in cells longer, and with higher enzyme afﬁnity,
156 J.A. Hess, M.K. Khasawneh / BBA Clinical 3 (2015) 152–161than unmodiﬁed MTX [35]. Cellular concentrations of polyglutamated
methotrexate rise even in the absence of circulating drug, until cellular
efﬂux begins [33]. Animals fed a diet rich in supplemented glutamine
showed not only a decreased incidence of MTX adverse effects, but
also an enhanced anti-tumor effect in cancer cells [6]. This effect was
also observed in the treatment of human tumors, and is likely secondary
to MTX polyglutamylation [36].
Intracellular polyglutamated MTX concentrations are an important
factor in achieving maximum pharmacologic effects in the treatment
of malignancy [35]. Rodent studies have shown that administration of
oral glutamine in conjunction with high dose MTX therapy was not
only associated with decreases in enteric mucositis, but also a 300%
increase in polyglutamated MTX concentrations within malignant cells
when compared to normal cells [36]. In a phase I trial based on these
rodent studies, nine patients with inﬂammatory breast cancer were
placed on a similar regimen. In this human study, one case of grade I
mucositis was reported and eight of the nine patients responded to
the chemotherapy regimen with a median survival of 35 months [36].
Asparaginases are frequently used in combination with MTX. The
process of MTX polyglutamylation inﬂuences the schedule dependent
response to combination therapy with L-asparaginase. Pre-treatment
of cancer cells with L-asparaginase leads to signiﬁcant interference
with MTX polyglutamation [37]. While its primary enzymatic activity
is focused on asparagine, L-asparaginases have varying levels of gluta-
minase activity that depends on the source of the enzyme. Post-MTX
treatment with L-asparaginase, the deamination of glutamine has a
synergistic effect on the activity of L-asparaginase [38,37]. Pretreatment
with asparaginase decreases tumor cell retention, and lowers the
tumoricidal effects, of MTX. The current literature suggests that this
effect is largely due to a massive deamination of glutamine being
required for optimal asparagine deamination [38].
Interference with cellular abilities to maintain the supply of
glutamine, glutamate and glutathione is detrimental, and often fatal,
to the cell. Glutaminase 2, a phosphate-activated mitochondrial en-
zyme, catalyzes the hydrolysis of glutamine to glutamate [39]. Loss of
this enzyme results in an effect similar to methotrexate therapy:
decreased NADH and glutathione with increased sensitivity to oxidant
stress [39]. Combination chemotherapy with metabolically active
agents, i.e., asparaginase, effectively starves the cancer cell of two
sources of fuel used to maintain functional output of the TCA cycle. In
settings of glutamine depletion, increased expression of asparagine syn-
thetase has been observed in hamster cell lines [40]. Pretreatment of
cancer cells withmethotrexate signiﬁcantly handicaps the regeneration
of NAD(P)H. Glutamine and glutamate shift from supplying intermedi-
ates of the TCA cycle into a signiﬁcant resource sink, de novo synthesis
of glutathione. As intracellular levels of glutamine decrease, expression
of asparagine synthetase increases with subsequent glutamine deple-
tion and increased ammonia production. With an evolving depletion
of glutamine and cellular shift toward increased asparagine synthesis,
the addition of L-asparaginase induces a starvation of asparagine and
glutamine with increased concentrations of aspartate, glutamate, and
ammonia. The restriction of both asparagine and glutamine have been
observed to induce expression of asparagine synthetase, glutamine
synthetase, IGF-I and -II, IGFBP-1, CHOP, ornithine decarboxylase,
oncogenes c-JUN and c-FOS and ribosomal proteins L17 and L25 [41].
In asparaginase-resistant cells, inhibition of glutamine synthetase has
been shown to block proliferation and decrease cellular viability [42].
Additionally, as expression of asparagine and glutamine synthetase
increases there is concomitant stabilization and up-regulation of the
Myc and BCL-2 oncoproteins [41].
5. Mitochondrial roles in oxidative stress and carcinogenesis
Endosymbiotic theory is currently the most accepted process of
mitochondrial origin. Two general assumptions accompany this
theory. The ﬁrst is that mitochondrial acquisition accompanied anaccumulation of atmospheric oxygen. The second marks a separation
of aerobic and anaerobic (assumed lack of mitochondria) eukaryotes.
The recent inclusion of various anaerobes to eukaryotic lineages is sec-
ondary to a much better understanding of variant “mitochondria-like”
organelles — i.e., hydrogenosomes, mitosomes. Recent biological and
geochemical theories propose an atmospheric oxygen increased long
before a noticeable increase in oxygen tension in oceanic waters. This
atmospheric oxygenation led to oxidation and solubilization of land
bound sulﬁde deposits making ocean waters increasingly anoxic and
sulﬁdic. In the light of this Proterozoic ocean chemistry theory for
mitochondrial endosymbiosis, one can rationalize that the beneﬁt of
mitochondrial acquisition was not solely an ability to provide ATP via
its utilization of oxygen but its ability to use electrons, as reduced
molecules, to buffer oxidant stresses in the environment. As a more
electronegative atom than sulfur, increasing concentrations of dissolved
oxygen would make it a much more efﬁcient recipient of those free
electrons [43].
Contemporarymitochondria are very dynamic organelles. They fuse,
divide, power metabolic detoxiﬁcation, generate stored energy and
servemany important regulatory and signaling functions. Recent litera-
ture describes a localizing mechanism of mitochondria with deﬁnitive
inﬂuence by the oxygen tension of the cell [44,45]. In hypoxic states,
mitochondria in pulmonary artery endothelial cells undergo inward
migration, via microtubules, and localize around the nucleus [44].
Mitochondrial respiration is a signiﬁcant producer of free radicals with
the electron transport chain being the primary source. This movement
is associated with a local increase in production of free radicals and
reactive oxygen species in the vicinity of the nucleus [44].
Mechanisms to mitigate damage from oxidative stresses produced
within the cell have evolved alongside the mitochondria. Superoxide
dismutase (SOD), catalase, glutathione (GSH) and thioredoxin are well
known scavengers of free radicals and their reactive metabolites [46].
Intermediates and products of glycolysis may also serve either antioxi-
dant roles, such as pyruvate, or serve as a substrate for an antioxidant
regenerating pathway as glucose-6-phosphate, glyceraldehyde-3-
phosphate via NADH production [47,46]. The absence of adequate oxy-
gen, presence of a dysfunctional electron transport chain, or a deﬁciency
of cofactors places the mitochondria at risk of increased free radical
production. A state of normal oxygen tension encouragesmitochondrial
localization in the cell periphery and a subsequent local increase in free
radical concentrations. For a metabolically normal cell, injury induces
the production of reactive oxygen species produced via NAD(P)H
oxidase and then secretion into the extracellular matrix to initiate the
process of healing. This peripheral increase in free radicals places cell
membrane components at risk. The hydroxyl radical, regardless of its
source, is one that may freely diffuse through cell membranes. One
membrane component particularly vulnerable to hydroxyl radicals is
arachidonic acid often esteriﬁed to membrane phospholipids. A class
of eicosanoids called isoprostanes are formed upon reaction of arachi-
donic acid with free radicals; i.e., hydroxyl radicals [48]. Isoprostanes
are isomers of the cyclo-oxygenase enzyme product prostaglandin F2
and will subsequently induce the same inﬂammatory cascade [49].
There is also some evidence to suggest the formation of thromboxane
A2 via isoprostane endoperoxide rearrangement [50]. In a cell with
poor antioxidant reserve, similar hypoxic events increase the likelihood
of subsequent DNA damage from those free radicals.
Mitochondria are arguably the most signiﬁcant physiologic players
in chemical metabolism. Beyond the ETC., reactions catalyzed via the
cytochrome P450 family of enzymes are a signiﬁcant source of free
radical production. Cytochrome P450 enzymes make up a superfamily
of heme-thiolate proteins involved in steroid synthesis and are respon-
sible for 75% of phase I drug metabolism [51–53]. The majority of these
enzymes are associated with NAD(P)H-reductases and found in either
the endoplasmic reticulum or the mitochondria [53]. An electron is
obtained fromNAD(P)H via the associated reductase enzyme and trans-
ferred to the substrate at the enzyme's binding site via its heme group
157J.A. Hess, M.K. Khasawneh / BBA Clinical 3 (2015) 152–161[51]. The overall efﬁciency of electron transfer from NAD(P)H to the
cytochrome P450 enzyme and then to its substrate can vary. Although
this reaction typically detoxiﬁes a chemical, it may also transform a
procarcinogen to its carcinogenic metabolite; i.e., 5-methylchrysene
from tobacco smoke [54].While some studies report an electron leakage
ﬂow of only 0.15%, in steroidogenic tissues the cytochrome P450
components outnumber electron transport chain components ten to
one [53]. The “leaked” electrons can react with a variety of molecules
to form free radicals, just as those from the electron transport chain.
In vitro studies show that MTX therapy decreases intracellular
concentrations of reduced glutathione [55]. While NAD(P)H is required
for regeneration of reduced glutathione, it is not for required for de novo
synthesis. In de novo synthesis, glutamate, cysteine, glycine and ATP are
used in an enzyme catalyzed reaction. Depletion of glutathione in serine
starved cells (a precursor to cysteine) has been associated with
impaired glycolysis and an elevation in cellular ROS [56]. Tumor
suppressor p53, in conjunctionwith the cyclin-dependent kinase inhib-
itor, p21, arrests cellular development and promoted cellular survival by
rapid shunting of exogenous serine into the glutathione synthesis
pathway [56]. In cells without p53, this shunt did not occur. The
resulting serine depletion and oxidative stress lead to not only impaired
proliferation, but also a reduction in cellular viability [56].
These rescue pathways must be supplied components in order to
preserve the cell and maintain homeostasis. Catabolism of cellular
components is a growing area of investigation into cancer metabolism
and centers on autophagy. Autophagy is the process in which cells
degrade and recycle macromolecules and organelles via two distinct
pathways; the ubiquitin-proteasome system (UP system) and the
lysosome [57]. Smaller, short-lived proteins are the typical degradation
targets of the UP system. However, the size and stability large protein
aggregates and organelles leave the lysosomal pathway as the most
effectivemeans of autophagy. Inmammalian cells, lysosomal autophagy
is directed by a chaperone systemmarkingmacromolecules and organ-
elles for digestion [58]. The most apparent beneﬁts of autophagy are
resultant decreases in damaged, unneeded or toxic cellular components
while producing raw materials for cellular metabolism [59].
While its pathways are not fully understood, the regulation of these
processes is intimately linked with their function; i.e., recycling cellular
components and providing fuel for cellular processes [60]. Cellular star-
vation is a powerful inducer of autophagy. A fall in intracellular amino
acid concentrations is another stimulant of autophagy. Constructing a
spectrum of starvation signals, nitrogen is an excellent marker of cellu-
lar nutrition. To clarify, in a very well supplied cell, amino acids would
activate cellular anabolic pathways via conjugated tRNA activation of
the Gcn protein kinases [61]. As amino acid concentrations drop, the
number of transamination and deamination reactions in the cell
increases to attenuate this lack of key amino acids. Cellular concentra-
tions of ammonia, especially in concert with glutaminolysis, serve as a
powerful regulator in the basal cellular autophagy rates [62]. Further
along the spectrum, however, total nitrogen starvation is a more potent
activator than either of the previous nitrogen-related stimulants [61].
Reactive oxygen species are also potent activators of autophagy.
Superoxide, in particular, has been found to be a major player in
the activation of reactive oxygen species induced autophagy. In
properly functioning cells, it is reduced to hydrogen peroxide and
then to water via SOD1, SOD2 and catalase or scavenged by one of
many different antioxidants present in the cell or in circulation. It
has been observed that not only do polymorphisms in the genes cod-
ing these proteins affect their efﬁcacy, but chronic therapy with MTX
also inﬂuences expression proﬁles with these genes [63]. When an-
tioxidant systems are overwhelmed, mitochondrial components
are at a very distinct geographical disadvantage to the effects of
free radicals and reactive oxygen species. Although the GSH
regenerating abilities of mitochondria are present, mitochondrial
autophagy, or mitophagy, may ensue if sufﬁciently injured or dam-
aged. This has been seen in association with signiﬁcant decreasesin the ratio of GSH/GSSG inducing mitophagy, while ample concen-
trations of GSH are inhibitory to the process [64].
2-Deoxyglucose (2DG), and glucose starvation, have been observed
to induce apoptosis in some cancer cells. Recent research has revealed
a dichotomy of effect depending on cellular conditions. In hypoxic envi-
ronments, 2DG and glucose starvation inhibit autophagic processes,
possibly through signiﬁcant decreases in ATP through PI3K III-Beclin1
complex blocking the effects of autophagy activating genes [65]. These
same conditions will activate autophagy in a normoxic environment
through separate pathways initiated by ROS formation [66,65]. This
dual effect could be explained by the utilization of glycolysis intermedi-
ates and end-products in mitochondrial redox buffering roles.
6. Mitochondrial metabolism and the cell cycle
Senescent thymocytes obtain 88% of ATP production occurs fromox-
idative glucose metabolism. However, when stimulated to proliferate,
86% of ATP production is obtained without oxidative phosphorylation,
by the conversion of glucose to lactate [10]. This shift to non-oxidative
ATP production pathways results in signiﬁcant increases, as much as
20-fold, in glucose utilization in proliferating cells [10,67]. Thismetabol-
ic redirection to aerobic glycolysis and lactate production offers several
beneﬁts for the proliferating cell [10]. These include the production of
numerous metabolic intermediates to serve as antioxidants, creation
of an acidic environment to improve oxygenation and stimulation of
angiogenesis via enzyme activation and the production of various
inﬂammatory mediators — all of additional beneﬁt to cancer cells in a
hypoxic environment [10]. Outside of the process of cell division, this
same metabolic redirection occurs during episodes of hypoxic stress.
Prior to cell division, mitochondrial mass expands largely for two
reasons. The ﬁrst is in preparation for increased metabolic demands of
replication. The second is the preparation for splitting of the parent cell's
mitochondrial population between two daughter cells. As with
mitochondrial localization induced by HIF, microtubules are involved
in mitochondrial changes seen in preparation for cell division [68].
Cellular progression of G1- to S-phase is dependent on a favorable
redox status in the cell and is a signiﬁcant signaling pathway [69]. If
we assume that the TCA cycle progresses at a constant rate and
increased inner membrane mitochondrial volume correlates with total
TCA cycle enzyme then the G1/S phase would have a high [NADH]/
[NAD+] redox status [70]. In addition to mitochondrial morphologic
changes, there is an associated decrease in ATP production due to
decreased NADH ﬂow through the electron transport change. High
concentrations of NAD(P)H have been shown to have multiple effects
on regulatory proteins, gene expression, directly or epigenetically, and
cell cycle progression.
Mitochondrial inner membrane production in HeLa cells, with func-
tional enzymatic capabilities, is completed by mid-S-Phase [70]. At this
point in the cell cycle, there is no increase in mitochondrial membrane
potential. Prior to entering M-Phase, there is a signiﬁcant increase in
mitochondrial mass and membrane potential, as much as 168% and
228% respectively, with less than a 20% increase in ATP [70]. There is a
noted discrepancy, and delay, between the cessation of innermitochon-
drial membrane accumulation, in mid-S phase, and the increase of
mitochondrial membrane potential prior to M-phase. Metabolism
during these transitional stages is highly dependent on glutamine for
cellular metabolic demands.When starved for glutamine, synchronized
HeLa cells do not progress fromG1- to S-phase or S- toG2/M-phase [71].
When those same cells are placed in media with glutamine without
glucose, the cell cycle does progress at these points, albeit at a slower
rate [71].
The effects of folate depletion and methotrexate therapy on the cell
cycle have been studied. Folic acid depleted HepG2 cells have been
observed and they tend to arrest in an S-phase with notable inhibition
of G2 phase progression [72]. Cell cycle arrest at these stages was
observed to precede apoptosis in this studywith those in S-phase arrest
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arrest the cell cycle S-Phase, i.e., an induced folate deﬁciency. The liter-
ature supports the observation of S-phase arrests in both low and high
dose methotrexate therapies [73–75]. Interestingly, a thorough evalua-
tion of these studies suggests a temporary blockade of G1 to S phase that
occurs in the ﬁrst few hours after administration of methotrexate and it
appears to be dose related [74,75].
The historical cytotoxic mechanism of MTX is felt to be a disruption
of DNA synthesis via its inhibition of DHFR. However, the antagonistic
effect of MTX on other NADPH-dependent oxidoreductases resulting
in decreasingNADHproduction and, subsequently, GSH depletion offers
a slightly more accurate model of toxicity [11,29,7,8,6,28]. Depletion of
reduced glutathione, GSH, has been observed to affect the cell cycle
similarly to both folate depletion and methotrexate therapy. GSH
depletion has not only been observed to restrict cell cycle progression
from G1 to S-phase, but also restrict DNA synthesis arresting cells in S-
Phase [76]. The authors of this study explain that the slightly less
pronounced inhibition of G1 to S-phase may be due to pathways
dependent on, in part, a separate pool of thiol proteins [76]. However,
the mechanism by which methotrexate interferes with cell cycle
progressions is not fully understood and studies are generally limited.
7. DNA damage and malignant transformation
Cellular hypoxia induces a peri-nuclear mitochondrial migration.
Applying the same cellular state of ﬂuctuating oxidative stress and
free radical production in the vicinity of the nucleus would place the
nuclear DNA at increased risk of damage. Beyond the risk for genetic
damage and mutation during chromosomal replication, the current ge-
nome proﬁle being expressed in a senescent cell would expose many
regulatory and functional sites to an even higher risk of damage. Many
commonly mutated tumor suppressor genes and oncogenes, P53, MYC
and BCL as examples, induce metabolic changes in non-transformed
cells in periods of high cellular stress [77–83]. Affecting amino acid me-
tabolism, mitochondrial function, glycolysis and autophagy, the end
function of these genes is to temporarily halt cellular self-destruction
while processes attempt to overcome that stress. A Pyrrhic victory of
sorts, these genes may prolong the life of the cell but at the cost of po-
tential mutation if recovery fails, leading to cancerous transformation.
The mitochondrial chromosome is at a much higher risk for damage
via this mechanism. Two important differences are present between
nuclear andmitochondrial DNA, the ﬁrst being thatmitochondrial chro-
mosomes are not protected via histones [84]. In nuclear DNA, genetic
material is wrapped around histones and physically protected, to
some degree, from the damaging effects of free radicals. The second
factor is that the status of cellular oxygen tension would likely have
no signiﬁcant effect on the proximity of free radicals produced by
mitochondria. Low level reactive oxygen species could be severe
enough to induce mtDNA damage if not adequately buffered.
Combining the two factors, i.e., a state of cellular hypoxia and
increased free radical production, would put the mitochondrial DNA at
a much higher risk for damage than nuclear DNA. Periods of chronic
reactive oxygen species exposure have been shown to damage mtDNA
and other macromolecules more extensively and with longer lasting
effect, than damage to nuclear DNA [85]. Whether its resultant acute
damage or epigenetic changes through chronic FR exposure of nuclear
or mitochondrial DNA, this process could be responsible for “locking”
cancer cells into this abnormal metabolism [86–90].
8. Mitochondria, evolution and cancer development
Genetic predispositions aside, the literature supports the postulate
that genetic mutations in most cancers are secondary to severe meta-
bolic and mitochondrial dysfunction leading to inappropriate and inad-
equate buffering of oxidant stresses. A better understanding of the
complex interactions of cellular metabolism, mitochondrial function,and oxidative stress appears to have very widespread implications in
the pathophysiology and treatment of disease [91–97]. Immediate
application of this review falls on the subject of chemotherapeutics
but applications may exist for the treatment or prevention of many
pathologies.
While exact environmental parameters of Proterozoic oceans are
under debate, an increased level of electrochemical redox stress from
dissolving land bound sulﬁde deposits prior to oceanic oxygenation is
certainly plausible [43]. Acquisition of an organelle with the sole pur-
pose of buffering changes in redox stress would undoubtedly increase
cellular ﬁtness, expand the number of tolerable environments and
allow for the evolution of more complex cellular processes [86–90]. Co-
incidentally or not, the acquisition of these organelles, and subsequent
stabilization of environmental redox status, is followed by a massive
increase in biodiversity known as the Cambrian Explosion that marks
the end of the Proterozoic Era.
Current understandings describe the primary mitochondrial role
as an oxygen dependent power plant with the primary role of ATP
production via oxidative phosphorylation. Research into mitochondrial
origins and the environmental redox status of early eukaryotic cellsmay
further expose early roles of the ancestral organelle. Investigations of
mitosomes and hydrogenosomes reveal organelles very similar tomito-
chondria, with reduced or non-existent ATP-producing functions [98].
Interestingly, all three organelles have in common the ability to create
and store reduced molecules for later use by the cell. Some research
suggests that molecular hydrogen, one product of hydrogenosomes,
may serve as an effective antioxidant and has been shown to decrease
area of infarction in rat brains affected by ischemia–reperfusion injuries
[99]. The mitochondrial currency of stored reduced molecules, NAD(P)
H, and its ratio to NAD+ has been shown to have intimate interactions
in the growth and metastasis of tumors. Excessive concentrations of
NAD(P)H in relation toNAD+have been shown tohave a positive effect
on the growth and metastasis of breast cancers [100].
Many cancers originate in hypoxic microenvironments. Detailed
studies have documented how characteristics of the tumor microenvi-
ronment can lead to signiﬁcant changes in tumor phenotypes. Survival
of these cells appears to be dependent, in part, upon mitochondrial
abilities to regenerate free radical scavengers to buffer oxidant stress.
Experimental studies have shown a dependence on mitochondrial and
cytosolic properties to perpetuate tumors. By placing normal and
tumor nuclei in tumor and normal cells respectively, normal daughter
cells were produced upon division of the tumor nuclei and normal cell
cytoplasm [101]. In the second population of cells, with normal nuclei
and tumor cytoplasmic contents, division resulted in the production of
more tumor cells or cell death [101].
The resultant metabolism of these cells becomes highly dependent
on the catabolism of amino acids, particularly glutamine, to preserve
the cell via regeneration of free radical scavengers.With this realization,
the Warburg effect seemingly covers only part of the metabolic
derangements seen in cancer. The increase in glycolysis and lactate
production may serve as a depository for nitrogen freed from trans-
amination reactions needed to fuel enzyme catalyzed reduction of
NAD(P)+. Methotrexate interferes with many enzymes involved in
reduction of NAD(P)+ to NAD(P)H and, more signiﬁcantly, cellular
abilities to buffer oxidative stress.
9. Discussion
Acquisition of the earlymitochondrial organelle led to increased cel-
lular ﬁtness, in part, due to its ability to buffer redox stresses secondary
to changes in the cells' immediate environment. This buffering function
increased cellular hardiness allowing survival during environmental
changes. Although part of a whole, individual cells throughout the
body are subject to changes and stresses in their own microenviron-
ments. Cellular metabolites serve as intermediate signals of the extra-
cellular environment to effect genetic expression. New understandings
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cellular redox buffering, metabolism and mitochondrial function are
more susceptible targets in cancer therapy than genomic attack. A bet-
ter understanding of metabolic pathways and the effects of other anti-
cancer agents on themmay offer signiﬁcant insight into paradoxical ef-
fects seen with many chemotherapeutic drugs. In consideration of the
known and unknown mechanism of many current pharmaceutical
agents in use today, it may be possible to fashion synergistic regimens
of medications for a variety of cancers once the characteristic metabolic
alterations of speciﬁc neoplasms are better understood.
The importance and function of the mitochondria and their changes
during the cell cycle also offer insight into peculiarities of other chemo-
therapeutic agents. In regard to the antimitotic chemotherapeutics,
such as paclitaxel, a proliferation rate paradox is described by these
agents selectively targeting of cells with high rates of division yet
these same agents will induce regression in tumors with low rates of
proliferation [102]. Beyond cell division, microtubules are highly
utilized in the intracellular localization ofmitochondria. Agents interfer-
ing with the proper function of microtubules likely interfere with the
purposeful migration and localization of mitochondria throughout the
cell cycle.
Recent targeting of cisplatin to increase mitochondrial uptake
increases its efﬁcacy in cancer cell lines that had previously grown resis-
tant. The classically described mechanism of the highly reactive mole-
cule, cisplatin, is based around the formation of adducts with proteins
and DNA. Though the nuclear DNA adducts formed during cellular
division are thought to be key markers of the anti-cancer mechanism
of cisplatin, there is a paradoxical effect in regard to cytotoxicity of
cisplatin in cells that are not actively dividing. Research has shown
that an accumulation of cisplatin in mitochondria may be the re-
sponsible mechanism for its toxicity in non-mitotic cells. Adducts
formed with mitochondrial DNA and proteins appear to increase
rates of ROS production and have also been shown to activate
caspases in enucleated cancer cells [103]. This mitochondrial path-
way of toxicity is reinforced by the observation of increased cisplatin
resistance in cells with dysfunctional mitochondria. As seen with
methotrexate, there is an observed reduction in cisplatin toxicity in
cells supplied with mitochondria-targeted antioxidants, particularly
in regard to nephrotoxicity [103].
Despite the cell's extensive ability to neutralize free radicals via
mitochondrially derived NAD(P)H, in a scenario of overwhelming
oxidant stress the reserve capabilities of endogenous and exogenous
antioxidantsmay be unable to defend the cell from the damaging effects
of free radicals. These stresses may be environmental or nutrition
related or due to the genetic predispositions of the cell. Iron, copper,
various forms of radiation, inﬂammation, smoke, vehicle exhaust, anti-
neoplastic drugs and ischemia/reperfusion injuries are all known to
increase cellular oxidants [104]. Down syndrome is associated with
increased oxidant stress secondary to over-expression of superoxide
dismutase relative to catalase and glutathione peroxidase [105–107].
The SOD1 gene coding for superoxide dismutase is found on chromo-
some 21, 21q22.1 [107]. Individuals with Down syndrome have lower
plasma total antioxidant status measured as reduced glutathione
[107]. This inborn dysfunctional ratio leads to an increased susceptibil-
ity to cellular oxidant stress. It is well known that patients with Down
syndrome are at an increased risk of not only malignancy, but also
Alzheimer's disease and adverse drug reactions to many chemothera-
peutic agents, including MTX. In addition to Down syndrome, similar
mitochondrial andmetabolic dysfunctions are accompanied by sensitiv-
ity to oxidant stresses in ataxia-telangiectasia, Fanconi anemia, and
Werner syndrome [106].
By better understanding the biochemical pathways and metabolism
of methotrexate and other chemotherapeutic agents, it may be possible
to improve tumoricidal responses from anticancer radiotherapy. The
mechanism of cellular toxicity from irradiation is the result of direct
DNA damage secondary to free radical formation and its damage tomolecules in close proximity. It seems plausible that tumor cells could
be “loaded” with methotrexate with co-administered glutamine
supplementation prior to irradiation. By coordinating radiotherapy
with peaking intracellular methotrexate polyglutamates with a serum
methotrexate nadir it may be possible to increase the cytotoxic effect
while decreasing radiation and collateral damage to healthy cells.
For millennia, the living cell has evolved mechanisms to preserve
itself and protect its genome at all costs. The mitochondrial organelle
appears to play a signiﬁcant role not only in the evolution of complex
life, but also in the development and maintenance of cancer cells.
Despite overwhelming stresses ranging from extreme starvation to
massive free radical attack, the cell persists. At the cost of growth and
detriment to its host, the cancer cell persists. When its metabolism
has “damaged” its cellular blueprints and reprogrammed cellular
physiology enough to thrive in its new environment, the cancer cell
proliferates, escapes its site of origin, settles elsewhere in its new
world and, yet again, persists.
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